LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Normal Cells and Cancer Cells Differentiated by Degree of Protein Phosphorylation

By LabMedica International staff writers
Posted on 09 Dec 2009
Print article
Cancer researchers have developed a method to differentiate cancer and normal cells at the molecular level based on different degrees of protein phosphorylation.

At the molecular level, cancers are heterogeneous diseases, arising from genetic factors, environmental carcinogens, and random, somatic mutation. Phosphorylation of proteins is a key regulator of protein activity, and in particular, modification of tyrosine residues modulates critical signaling and control processes. In cancers, aberrant phosphorylation status of key residues (its presence or absence) has been observed and documented in many studies.

Investigators at Boston University (MA, USA) collaborated with specialists at Cell Signaling Technology (Danvers, MA, USA) in order to apply the "Phosphoscan" methodology to establish a comparative profile of the phosphorylation properties of proteins in normal and cancer cells.

They reported in the November 25, 2009, issue of the journal PLoS ONE that a large set of sites were differentially phosphorylated in tumors, many of which can be used as direct targets for new drugs. Furthermore they employed a novel computational approach to perform a protein variant of gene set enrichment analysis that showed that certain pathways were differentially activated, based on their global phosphorylation status. A relatively small number of phosphorylated peptides observed in that data could discriminate between normal tissue and tumors with a high degree of sensitivity and specificity.

"Identifying the phosphorylation status of proteins in cancer cells versus normal cells provides us with a unique ability to understand and perhaps intervene with the command and control center of cancer cells," said contributing author Dr. Simon Kasif, professor of biomedical engineering at Boston University. "Drugs are most effective on cancers when they attack the proteins that are activated."

Related Links:
Boston University
Cell Signaling Technology


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Myeloperoxidase Assay
IDK MPO ELISA

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.